CABIO(SH:688089)2020-10-28 16:00Financial Performance - Operating income for the first nine months rose by 2.19% to CNY 236,256,283.53 compared to the same period last year[6] - Net profit attributable to shareholders increased by 14.69% to CNY 110,107,131.47 for the first nine months[6] - The total net profit for the third quarter was CNY 73,382,893.58, reflecting a 10.71% increase year-on-year[6] - Total operating revenue for Q3 2020 was CNY 85,296,622.21, a slight increase of 1.47% compared to CNY 84,061,610.73 in Q3 2019[26] - Net profit for Q3 2020 reached CNY 40,296,130.64, representing a 20.00% increase from CNY 33,307,091.17 in Q3 2019[28] - Total profit for the first three quarters of 2020 was approximately ¥122.24 million, compared to ¥111.40 million in the same period of 2019, reflecting a growth of 9.92%[32] Cash Flow - Net cash flow from operating activities surged by 57.78% to CNY 115,354,810.57 year-to-date[6] - The company's operating cash flow increased by 57.78% to ¥115,354,810.57, driven by increased sales collections[16] - Cash flow from operating activities for the first three quarters of 2020 was approximately ¥115.35 million, a significant increase from ¥73.11 million in the same period of 2019[35] - The company reported a net cash outflow from investing activities of approximately ¥569.14 million for the first three quarters of 2020[35] - Cash and cash equivalents at the end of the period were RMB 318,358,715.02, down from RMB 837,921,073.56 at the beginning of the year[37] Assets and Liabilities - Total assets increased by 3.84% to CNY 1,347,692,587.72 compared to the end of the previous year[6] - Current assets totaled CNY 1,098,716,982.84, slightly down from CNY 1,099,062,852.60 in the previous year, indicating a decrease of about 0.03%[19] - Total liabilities decreased to CNY 44,521,637.86 from CNY 48,256,358.50, a reduction of approximately 7.3%[20] - Total liabilities as of Q3 2020 amounted to CNY 53,976,286.15, an increase from CNY 46,764,345.24 in the previous year[24] - The company reported a total equity of RMB 1,249,575,165.09, consistent with the previous period[41] Shareholder Information - Total number of shareholders reached 5,360[13] - Wuhan Xiwang Bioengineering holds 53,100,000 shares, representing 44.25% of total shares[13] - The number of shares held by the top ten unrestricted shareholders includes 1,285,289 shares held by the National Social Security Fund[14] Research and Development - R&D expenditure as a percentage of operating income decreased by 0.96 percentage points to 4.98%[8] - Research and development expenses for Q3 2020 were CNY 3,770,614.15, a decrease of 36.14% from CNY 5,906,335.71 in Q3 2019[27] - The company plans to continue expanding its investment in new projects and technologies[16] Investment Activities - Long-term equity investments increased by 422.41% to ¥67,724,731.98, primarily due to investments in Pharmamark Nutrition Pty Ltd and Suzhou Dingshi Huize Biotechnology Investment Fund[15] - Investment income rose significantly to ¥11,509,054.80, an increase of 8,748.77% compared to the previous year[15] - The company reported a decrease in prepayments by RMB 999,885.13, reflecting changes in contract liabilities[44] Financial Expenses - The company’s financial expenses decreased significantly due to increased interest income[15] - The company incurred a financial expense of approximately ¥604.46 thousand in Q3 2020, compared to a financial income of approximately ¥733.11 thousand in Q3 2019[32]